BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 22243666)

  • 1. The phantom menace of prostate cancer screening.
    Ghani KR; Trinh QD; Menon M
    BJU Int; 2012 Feb; 109(3):324-6. PubMed ID: 22243666
    [No Abstract]   [Full Text] [Related]  

  • 2. Screening for prostate cancer.
    Ruffin MT
    J Fam Pract; 1999 Aug; 48(8):581-2. PubMed ID: 10496634
    [No Abstract]   [Full Text] [Related]  

  • 3. Blinded and uniform causes of death verification in cancer screening: a major influence on the outcome of a prostate cancer screening trial?
    Otto SJ; van Leeuwen PJ; Hoekstra JW; Merckelbach JW; Blom JH; Schröder FH; Roobol MJ; de Koning HJ
    Eur J Cancer; 2010 Nov; 46(17):3061-7. PubMed ID: 21047587
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prostate cancer screening and mortality: comparison of recent randomized controlled clinical trials.
    Mian BM
    Urol Oncol; 2010; 28(3):233-6. PubMed ID: 20097584
    [No Abstract]   [Full Text] [Related]  

  • 5. Screening for prostate cancer remains controversial.
    Stark JR; Mucci L; Rothman KJ; Adami HO
    BMJ; 2009 Sep; 339():b3601. PubMed ID: 19778971
    [No Abstract]   [Full Text] [Related]  

  • 6. Prostate specific antigen for detecting early prostate cancer.
    Ilic D; Green S
    BMJ; 2009 Sep; 339():b3572. PubMed ID: 19778970
    [No Abstract]   [Full Text] [Related]  

  • 7. Epilogue: different approaches for prostate cancer screening in the EU?
    Schröder FH; Denis L; Roobol MJ
    Eur J Cancer; 2010 Nov; 46(17):3120-5. PubMed ID: 21047595
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PSA levels and cancer detection rate by centre in the European Randomized Study of Screening for Prostate Cancer.
    Otto SJ; Moss SM; Määttänen L; Roobol M; Zappa M; Nelen V; Kwiatkowski M; Villers A; Hugosson J; Sanchez AB; de Koning HJ
    Eur J Cancer; 2010 Nov; 46(17):3053-60. PubMed ID: 21047586
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Screening for prostate cancer: prostate-specific antigen testing is not effective.
    Hitzeman N; Molina M
    Am Fam Physician; 2011 Apr; 83(7):802-4. PubMed ID: 21524045
    [No Abstract]   [Full Text] [Related]  

  • 10. Perspective on prostate cancer screening.
    Rogers CS
    Int J Clin Pract; 2011 Jan; 65(1):31-4. PubMed ID: 21155942
    [No Abstract]   [Full Text] [Related]  

  • 11. Cost-effectiveness of prostate specific antigen screening in the United States: extrapolating from the European study of screening for prostate cancer.
    Shteynshlyuger A; Andriole GL
    J Urol; 2011 Mar; 185(3):828-32. PubMed ID: 21239021
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Validity and legacy of prostate-specific antigen (PSA) and PSA-based parameters and isoforms in the new millennium.
    Djavan B
    Eur Urol; 2010 Jun; 57(6):928-9. PubMed ID: 20304552
    [No Abstract]   [Full Text] [Related]  

  • 13. Prostate-specific antigen: a new(ish) study.
    Harv Mens Health Watch; 2010 Nov; 15(4):6-8. PubMed ID: 21166115
    [No Abstract]   [Full Text] [Related]  

  • 14. Rural residence and prostate cancer screening with prostate-specific antigen.
    Stamatiou K; Skolarikos A
    Rural Remote Health; 2009; 9(2):1227. PubMed ID: 19594290
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Surgery no better than observation for localized prostate cancer.
    Printz C
    Cancer; 2012 Nov; 118(22):5452-3. PubMed ID: 23129387
    [No Abstract]   [Full Text] [Related]  

  • 16. Balancing the harms and benefits of early detection of prostate cancer.
    van Leeuwen PJ; Connolly D; Tammela TL; Auvinen A; Kranse R; Roobol MJ; Schroder FH; Gavin A
    Cancer; 2010 Oct; 116(20):4857-65. PubMed ID: 20839233
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostate specific antigen - useful screening tool or potential liability?
    Mahar P; Sengupta S; Ludlow K; Corcoran N
    Aust Fam Physician; 2010 Aug; 39(8):598-600. PubMed ID: 20877758
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Screening for prostate cancer with serum prostate-specific antigen : what should we recommend while waiting for randomized clinical trial results?
    Davis JW
    Cancer; 2008 Dec; 113(11):3067-8. PubMed ID: 18932255
    [No Abstract]   [Full Text] [Related]  

  • 19. [Early detection of prostatic carcinoma: Is PSA screening suitable?].
    Kaulen H
    Dtsch Med Wochenschr; 2003 May; 128(18):977. PubMed ID: 12755136
    [No Abstract]   [Full Text] [Related]  

  • 20. Two randomized screening trials with prostate cancer mortality, two interim results: a consideration of usual-care window in screening trials.
    Song Y
    Contemp Clin Trials; 2010 Jul; 31(4):378-80. PubMed ID: 20450987
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.